首站-论文投稿智能助手
典型文献
DeepPurpose-based drug discovery in chondrosarcoma
文献摘要:
Background:Chondrosarcoma(CS)is the second most common primary bone tumor,accounting for approximately 30%of all malignant bone tumors.Unfortunately,the efficacy of currently available drug therapies is limited.Therefore,this study aimed to explore drug therapies for CS using novel computational methods.Methods:In this study,text mining,GeneCodis STRING,and Cytoscape were used to identify genes closely related to CS,and the Drug Gene Interaction Database(DGIdb)was used to select drugs targeting the genes.Drug-target interaction prediction was performed using DeepPurpose,to finally obtain candidate drugs with the highest predicted binding affinities.Results:Text-mining searches identified 168 genes related to CS.Gene enrichment and protein-protein interaction analysis generated 14 genes representing 10 pathways using GeneCodis,STRING,and Cytoscape.Seventy drugs targeting genes closely related to CS were analyzed using DGIdb.DeepPurpose recommended 25 drugs,including integrin beta 3 inhibitors,hypoxia-inducible factor 1 alpha inhibitors,E1 A binding protein P300 inhibitors,vascular endothelial growth factor A inhibitors,AKT1 inhibitors,tumor necrosis factor inhibitors,transforming growth factor beta 1 inhibitors,interleukin 6 inhibitors,mitogen-activated protein kinase 1 inhibitors,and protein tyrosine kinase inhibitors.Conclusion:Drug discovery using in silico text mining and DeepPurpose may be an effective method to explore drugs targeting genes related to CS.
文献关键词:
作者姓名:
Jianrui Li;Mingyue Shi;Zhiwei Chen;Yuyan Pan
作者机构:
Department of Plastic and Reconstructive Surgery,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Big Data and Artificial Intelligence Center,Zhongshan Hospital,Fudan University,Shanghai 200032,China
引用格式:
[1]Jianrui Li;Mingyue Shi;Zhiwei Chen;Yuyan Pan-.DeepPurpose-based drug discovery in chondrosarcoma)[J].中国整形与重建外科(英文),2022(04):158-165
A类:
DeepPurpose,Chondrosarcoma
B类:
discovery,chondrosarcoma,Background,CS,second,most,common,primary,bone,accounting,approximately,malignant,tumors,Unfortunately,efficacy,currently,available,therapies,limited,Therefore,this,study,aimed,explore,using,novel,computational,methods,Methods,text,mining,GeneCodis,STRING,Cytoscape,were,used,identify,genes,closely,related,Drug,Interaction,Database,DGIdb,was,select,drugs,targeting,interaction,prediction,performed,finally,obtain,candidate,highest,predicted,binding,affinities,Results,Text,searches,identified,enrichment,protein,analysis,generated,representing,pathways,Seventy,analyzed,recommended,including,integrin,beta,inhibitors,hypoxia,inducible,alpha,E1,P300,vascular,endothelial,growth,AKT1,necrosis,transforming,interleukin,mitogen,activated,kinase,tyrosine,Conclusion,silico,may,effective
AB值:
0.507793
相似文献
Drug repurposing for cancer treatment through global propagation with a greedy algorithm in a multilayer network
Xi Cheng;Wensi Zhao;Mengdi Zhu;Bo Wang;Xuege Wang;Xiaoyun Yang;Yuqi Huang;Minjia Tan;Jing Li-Department of Bioinformatics and Biostatistics,School of Life Sciences and Biotechnology,Shanghai Jiao Tong University,Shanghai 200240,China;The Chemical Proteomics Center and State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Key Laboratory of Tissue Microenvironment and Tumor,Shanghai Institute of Nutrition and Health,Shanghai Institutes for Biological Sciences,University of Chinese Academy of Sciences,Chinese Academy of Sciences(CAS),Shanghai 200031,China
Systematic screening reveals synergistic interactions that overcome MAPK inhibitor resistance in cancer cells
Yu Yu;Minzhen Tao;Libin Xu;Lei Cao;Baoyu Le;Na An;Jilin Dong;Yajie Xu;Baoxing Yang;Wei Li;Bing Liu;Qiong Wu;Yinying Lu;Zhen Xie;Xiaohua Lian-Department of Cell Biology,Basic Medical College,Army Medical University(Third Military Medical University),Chongqing 400038,China;MOE Key Laboratory of Bioinformatics and Bioinformatics Division,Center for Synthetic and System Biology,Department of Automation,Beijing National Research Center for Information Science and Technology,Tsinghua University,Beijing 100084,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Thoracic Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China;Beijing Syngentech Co.,Ltd,Beijing 102206,China;School of Life Sciences,Tsinghua University,Beijing 100084,China;The Comprehensive Liver Cancer Center,The 5th Medical Center of PLA General Hospital,Beijing 100039,China
The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
Jia Lu;Ting Li;Zhichao Liao;Hui Yu;Yongtian Zhao;Haixiao Wu;Zhiwu Ren;Jun Zhao;Ruwei Xing;Sheng Teng;Yun Yang;Xiangchun Li;Kexin Chen;Jonathan Trent;Jilong Yang-Department of Bone and Soft Tissue Tumor,2Department of Infection Management,3Key Laboratory of Molecular Cancer Epidemiology,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;YuceBio Technology Co.,Ltd.,Shenzhen 518172,China;Department of Epidemiology and Biostatistics,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;Sarcoma Multidisciplinary Program,Sylvester Comprehensive Cancer Center,The University of Miami,Miami,FL 33136,USA
Hypoxia-inducible factor-2α and its missense mutations: potential role in HCC diagnosis, progression, and prognosis and underlying mechanism
Jun Li;Yibo Yan;Ganxin Wang;Zaozao Huang-Emergency Department,Liyuan Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430077,China;Division of Cardiology,Liyuan Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430077,China;Division of Oncology,Liyuan Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430077,China;Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Yangchunhu Community Hospital,Liyuan Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430077,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。